# Basking Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/basking-biosciences

- Industry: Healthcare Specialists
- Headquarters: US
- Website: www.baskingbiosciences.com
- Total disclosed funding: $60M
- Latest round: Series B (Jan 30, 2024)
- Investors on record: 10

## About

Founded in 2019 and based in Ohio, US, Basking Biosciences, Inc., operates as a healthcare specialist that develops a thrombolytic therapy for acute ischemic stroke. The company was co-founded by Dr. Bruce Sullenger of Duke University and Dr. Shahid Nimjee of The Ohio State University founded the company. Mr. Richard Shea is the CEO of the company. The company developed DTRI-025 in Q4 2020. In December 2020, the company raised USD 5.4 million in seed funding from investors Rev1 Ventures, Broadview Ventures and Viva BioInnovator.

The company focuses on exploiting the properties of RNA biochemistry to develop aptamers with high affinity and specificity against proteins involved in coagulation and hemostasis. The company develops the first reversible thrombolytic therapy for Acute Ischemic Stroke (AIS). The solution of company includes DTRI-031 and it can inhibits von Willebrand Factor (vWF). And its solution DTRI-025 is continuing IND-enabling development.

## Funding rounds

- Series B, Jan 30, 2024, $55M — ARCH Venture Partners, Insight Partners, RTW Investments, Ohio State University, Rev1 Ventures, Solas BioVentures, Longview Ventures, Platanus Ventures
- Seed, Dec 7, 2020, $5.4M — Broadview Ventures, Rev1 Ventures, Viva Biotech Holdings

## Investors

- Broadview Ventures (https://capitalatlas.ai/funds/broadview-ventures) — Seed
- Rev1 Ventures (https://capitalatlas.ai/funds/rev1-ventures) — Seed, Series B
- Viva Biotech Holdings — Seed
- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series B
- Insight Partners (https://capitalatlas.ai/funds/insight-partners) — Series B
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series B
- Ohio State University — Series B
- Solas BioVentures (https://capitalatlas.ai/funds/solas-bioventures) — Series B
- Longview Ventures — Series B
- Platanus Ventures (https://capitalatlas.ai/funds/platanus-ventures) — Series B